Literature DB >> 14627993

beta1-integrin mediates asbestos-induced phosphorylation of AKT and ERK1/2 in a rat pleural mesothelial cell line.

Antje Berken1, Josef Abel, Klaus Unfried.   

Abstract

Integrin-mediated signalling has been implicated in asbestos-induced carcinogenesis. In studies here, we examined signal transduction events associated with integrin-directed cell reactions triggered by crocidolite asbestos in the pleural mesothelial cell line 4/4 RM-4. Crocidolite fibres induced a significant time- and dose-dependent activation of the extracellular-signal-regulated kinases ERK1 and ERK2. ERK activation was specifically inhibited by integrin-blocking agents, that are integrin-binding peptides containing the sequence arginine-glycine-aspartic acid (RGD), and monoclonal antibodies against the integrin beta1-chain. Integrin-dependent activation of ERK1/2 in response to asbestos appeared to be independent of focal adhesion kinase pp125FAK (FAK) since FAK autophosphorylation remained unaffected in crocidolite-exposed mesothelial cells. Instead, we observed striking similarities in the kinetics of asbestos-induced ERK1/2 responses and phosphorylation of protein kinase B (AKT) at serine 473, a possible target residue for integrin-linked kinase. As with ERK activation, asbestos-induced AKT stimulation was significantly blocked by both the RGD-peptide and the beta1-integrin antibodies. These studies are the first to establish that in mesothelial cells ERK1/2 and AKT are simultaneously phosphorylated upon asbestos exposure in a beta1-integrin-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627993     DOI: 10.1038/sj.onc.1207195

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Integrin-Linked Kinase (ILK) Deletion Disrupts Oligodendrocyte Development by Altering Cell Cycle.

Authors:  Rashad Hussain; Wendy B Macklin
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

2.  Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.

Authors:  Stefan B Watzka; Florian Posch; Harvey I Pass; Raja M Flores; Gregory E Hannigan; David Bernhard; Michael Weber; Michael R Mueller
Journal:  Eur J Cardiothorac Surg       Date:  2012-10-07       Impact factor: 4.191

Review 3.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Authors:  Brooke T Mossman; Arti Shukla; Nicholas H Heintz; Claire F Verschraegen; Anish Thomas; Raffit Hassan
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307

4.  SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis.

Authors:  Thomas Henzi; Walter-Vincent Blum; Martine Pfefferli; Tadeusz J Kawecki; Valerie Salicio; Beat Schwaller
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

5.  Doxycycline inhibits leukemic cell migration via inhibition of matrix metalloproteinases and phosphorylation of focal adhesion kinase.

Authors:  Chunhuai Wang; Ru Xiang; Xiangzhong Zhang; Yunxian Chen
Journal:  Mol Med Rep       Date:  2015-05-25       Impact factor: 2.952

6.  A natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancer.

Authors:  Do Young Lim; Seung Ho Shin; Mee-Hyun Lee; Margarita Malakhova; Igor Kurinov; Qiong Wu; Jinglong Xu; Yanan Jiang; Ziming Dong; Kangdong Liu; Kun Yeong Lee; Ki Beom Bae; Bu Young Choi; Yibin Deng; Ann Bode; Zigang Dong
Journal:  Oncotarget       Date:  2016-06-07

7.  Non-Canonical Activation of the Epidermal Growth Factor Receptor by Carbon Nanoparticles.

Authors:  Daniel Stöckmann; Tim Spannbrucker; Niloofar Ale-Agha; Philipp Jakobs; Christine Goy; Nadine Dyballa-Rukes; Tamara Hornstein; Alexander Kümper; Annette Kraegeloh; Judith Haendeler; Klaus Unfried
Journal:  Nanomaterials (Basel)       Date:  2018-04-23       Impact factor: 5.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.